Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.

Gynecologic Oncology
David M HymanDouglas A Levine

Abstract

BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction. We conducted a retrospective analysis of patients with FIGO stage IIIC-IV high-grade serous ovarian cancer classified for the presence or absence of germline BRCA mutations. The primary outcome was tumor-debulking status categorized as complete gross resection (0mm), optimal but visible disease (1-10 mm), or suboptimal debulking (>10 mm) following primary surgical cytoreduction. Overall survival by residual tumor size and BRCA status was also assessed as a secondary endpoint. Data from 367 patients (69 BRCA mutated, 298 BRCA wild-type) were analyzed. Rate of optimal tumor debulking (0-10 mm) in BRCA wild-type and BRCA-mutated patients were 70.1% and 84.1%, respectively (P=0.02). On univariate analysis, increasing age (10-year OR, 1.33; 95% CI, 1.07-1.65; P=0.01) and wild-type BRCA status (OR, 0.47; 95% CI, 0.23-0.94, P=0.03) were both significantly associated with suboptimal surgical outcome. On multivariate analysis, BRCA mutation status was no longer associated with residual tumor volume (OR...Continue Reading

References

Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert E BristowF J Montz
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren ScheuerKenneth Offit
Sep 28, 2002·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·P A ShawI J Jacobs
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sunil R LakhaniDouglas F Easton
Oct 20, 2004·Gynecologic Oncology·Gamal H EltabbakhAnne Morgan
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allison E AxtellChristine H Holschneider
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William E WinterUNKNOWN Gynecologic Oncology Group Study
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William E WinterUNKNOWN Gynecologic Oncology Group
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela ChetritSiegal Sadetzki
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charlie GourleyMichelle Ferguson
Sep 8, 2010·The New England Journal of Medicine·Ignace VergoteUNKNOWN NCIC Clinical Trials Group
Sep 25, 2010·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·C FotopoulouJ Sehouli
Nov 19, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J GallagherN D Kauff
Jun 21, 2011·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Mar 1, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M Carolina ReyesRobert A Soslow
Aug 20, 2014·BioMed Research International·Giulia GirolimettiDaniela Turchetti
Jun 24, 2016·Gynecologic Oncology·Beyhan AtasevenAndreas du Bois
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam N RosenthalUNKNOWN United Kingdom Familial Ovarian Cancer Screening Study collaborators
Apr 7, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Luis M ChivaAntonio Gonzalez-Martin
Mar 27, 2019·Cancers·Ainhoa MadariagaAmit M Oza
Jun 12, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Chen NahshonOfer Lavie
Feb 14, 2020·The New England Journal of Medicine·Robert L Coleman
Nov 23, 2020·Annals of Surgical Oncology·Felipe Leonardo EstatiAlexandre André Balieiro Anastácio da Costa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.